- Recent CE mark for CEREGLIDE™ 92 Catheter System supports upcoming European launch of super-bore aspiration and access technology
- Encore presentation of MEMBRANE a randomized controlled trial evaluating TRUFILL® n-BCA for middle meningeal artery (MMA) embolization in the treatment of chronic subdural hematoma (cSDH)
Irvine, CA, September 4, 2025 – Johnson & Johnson MedTech, a leader in neurovascular care, will highlight its latest clinical and technological advancements at the 2025 European Society of Minimally Invasive Neurological Therapy (ESMINT) Annual Congress in Marseilles, France. The company will feature an encore podium presentation of the MEMBRANE study and host a scientific symposium focused on CEREGLIDE ™ 92 – “Europe’s latest Superbore Aspiration Catheter”. These activities coincide with the recent CE Mark for the CEREGLIDE™ 92 Aspiration System, a next-generation super-bore catheter designed for the removal of emboli and thrombi from the neurovasculature.
“The ESMINT Congress offers a unique opportunity to bring the European neurovascular community together around the science and procedural advances shaping the future of stroke and neurovascular care,” said Christian Cuzick, Worldwide President, Neurovascular, Johnson & Johnson MedTech. “From data on cSDH to the CE Mark for our CEREGLIDE ™ 92 Aspiration System, we’re continuing to expand our portfolio to support physicians in achieving safer, more effective outcomes across a wide range of neurovascular conditions.”
The CEREGLIDE™ 92 Aspiration System features a .092” inner diameter super bore catheter with the INNERGLIDE™ 9 Delivery Aid. It offers BRITE-LINE™ full-length fluoroscopic visibility and TruCourse™ Technology for enhanced trackability and tip control. It is designed for aspiration and to support navigation and delivery of interventional devices throughout the cerebral vasculature, including in procedures where distal access1 and catheter stability are critical. CEREGLIDE 92 was introduced in the U.S. earlier this year, and Johnson & Johnson plans to initiate a phased rollout of CEREGLIDE™ 92 across select European markets this autumn, expanding access to next-generation super bore catheter technology for neurovascular interventions.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more information, visit here and connect on LinkedIn and X.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to CEREGLIDE 92™ catheter system. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at sec.gov, jnj.com, investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Media contact:
Anna Loring
[email protected]
EM_NEU_ISCH_405316
©Johnson & Johnson and its affiliates 2025